Pharvaris N.V.
PHVS•NASDAQ•Healthcare•Biotechnology

About Pharvaris

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOBerndt Axel Modig
Founded2015
IPO DateFebruary 5, 2021
Employees108
CountrySwitzerland
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyEUR - EUR
TypeStock

Contact Information

Websitepharvaris.com
Phone31 712036410
Address
Grafenauweg 8 Zug, 6300 Switzerland

Corporate Identifiers

CIK0001830487
CUSIPN69605108
ISINNL00150005Y4
SIC2834

Leadership Team & Key Executives

Berndt Axel Edvard Modig CPA, M.B.A.
Co-Founder, Chief Executive Officer and Executive Director
David W. Nassif J.D.
Chief Financial Officer, Chief Legal Officer and Corporate Secretary
Anna Nijdam M.Sc., R.A.
Head of Strategic Finance and Principal Accounting Officer
Dr. Stefan Abele Ph.D.
Chief Technology Operations Officer
Annick Deschoolmeester
Chief Human Resources Officer
Dr. Peng Lu M.D., Ph.D.
Chief Medical Officer
Dr. Anne A. Lesage Ph.D.
Chief Early Development Officer
Wim Souverijns Ph.D.
Chief Commercial Officer
Maryann Cimino
Director of Corporate Relations